Loading...

You're on the old version of Simply Wall St. We will no longer be supporting this site, so we recommend you switch to our brand new platform.

Moderna

DB:0QF
Snowflake Description

Flawless balance sheet with limited growth.

The Snowflake is generated from 30 checks in 5 different areas, read more below.
0QF
DB
$13B
Market Cap
  1. Home
  2. DE
  3. Pharmaceuticals & Biotech
Company description

Moderna, Inc., a clinical stage biotechnology company, develops therapeutics and vaccines based on messenger RNA for the treatment of infectious diseases, immuno-oncology, rare diseases, and autoimmune and cardiovascular diseases. The last earnings update was 39 days ago. More info.


Add to Portfolio Compare Print
  • Moderna has significant price volatility in the past 3 months.
0QF Share Price and Events
7 Day Returns
20.8%
DB:0QF
-0.7%
DE Biotechs
-0.6%
DE Market
1 Year Returns
27.3%
DB:0QF
-13.2%
DE Biotechs
-20.9%
DE Market
0QF Shareholder Return
  7 Day 30 Day 90 Day 1 Year 3 Year 5 Year
Moderna (0QF) 20.8% 22.7% 95.7% 27.3% - -
DE Biotechs -0.7% -8.2% -21% -13.2% 13.2% -11.8%
DE Market -0.6% -18.6% -26.2% -20.9% -25.8% -31.8%
1 Year Return vs Industry and Market
  • 0QF outperformed the Biotechs industry which returned -13.2% over the past year.
  • 0QF outperformed the Market in Germany which returned -20.9% over the past year.
Price Volatility
Industry
5yr Volatility vs Market

Value

 Is Moderna undervalued based on future cash flows and its price relative to the stock market?

Value is all about what a company is worth versus what price it is available for. If you went into a grocery store and all the bananas were on sale at half price, they could be considered undervalued.
INTRINSIC VALUE BASED ON FUTURE CASH FLOWS
  • It is not possible to calculate the future cash flow value for Moderna. This is due to cash flow or dividend data being unavailable. The share price is €31.9.
PRICE RELATIVE TO MARKET
We can also value a company based on what the stock market is willing to pay for it. This is similar to the price of fruit (e.g. Mangoes or Avocados) increasing when they are out of season, or how much your home is worth.

The amount the stock market is willing to pay for Moderna's earnings, growth and assets is considered below, and whether this is a fair price.
Price based on past earnings
Are Moderna's earnings available for a low price, and how does this compare to other companies in the same industry?
Raw Data
DB:0QF PE (Price to Earnings) Ratio Data Sources
Data Point Source Value
Earnings Per Share * Company Filings (2019-12-31) in USD $-1.55
NasdaqGS:MRNA Share Price ** NasdaqGS (2020-04-03) in USD $34.84
Europe Biotechs Industry PE Ratio Median Figure of 24 Publicly-Listed Biotechs Companies 40.67x
Germany Market PE Ratio Median Figure of 401 Publicly-Listed Companies 16.57x

* Trailing twelve months (TTM) annual GAAP earnings per share excluding extraordinary items.

** Primary Listing of Moderna.

DB:0QF PE (Price to Earnings) Ratio Calculation
Calculation Outcome
PE Ratio

= NasdaqGS:MRNA Share Price ÷ EPS (both in USD)

= 34.84 ÷ -1.55

-22.42x

Learn more about our ratios and growth rates in Simply Wall St’s analysis model >

  • Moderna is loss making, we can't compare its value to the Europe Biotechs industry average.
  • Moderna is loss making, we can't compare the value of its earnings to the Germany market.
Price based on expected Growth
Does Moderna's expected growth come at a high price?
Raw Data
DB:0QF PEG (Price to Earnings to Growth) Ratio Data Sources
Data Point Source Value
PE Ratio See PE Ratio Section -22.42x
Net Income Annual Growth Rate See Future Growth Section.
Line of Best Fit* through Consensus Estimate Earnings of 11 Analysts
0%per year
Europe Biotechs Industry PEG Ratio Median Figure of 19 Publicly-Listed Biotechs Companies 1.62x
Germany Market PEG Ratio Median Figure of 256 Publicly-Listed Companies 1.17x

*Line of best fit is calculated by linear regression .

Learn more about our ratios and growth rates in Simply Wall St’s analysis model >

  • Unable to calculate PEG ratio for Moderna, we can't assess if its growth is good value.
Price based on value of assets
What value do investors place on Moderna's assets?
Raw Data
DB:0QF PB (Price to Book) Ratio Data Sources
Data Point Source Value
Book Value per Share Company Filings (2019-12-31) in USD $3.49
NasdaqGS:MRNA Share Price * NasdaqGS (2020-04-03) in USD $34.84
Germany Biotechs Industry PB Ratio Median Figure of 14 Publicly-Listed Biotechs Companies 3.33x
Germany Market PB Ratio Median Figure of 572 Publicly-Listed Companies 1.44x
DB:0QF PB (Price to Book) Ratio Calculation
Calculation Outcome
PB Ratio

= NasdaqGS:MRNA Share Price ÷ Book Value per Share (both in USD)

= 34.84 ÷ 3.49

9.98x

* Primary Listing of Moderna.

Learn more about our ratios and growth rates in Simply Wall St’s analysis model >

  • Moderna is overvalued based on assets compared to the DE Biotechs industry average.
X
Value checks
We assess Moderna's value by looking at:
  1. Is the discounted cash flow value less than 20%, or 40% of the share price? (2 checks) ( Click here or on bar chart for details of DCF calculation. )
  2. Is the PE ratio less than the market average, and/ or less than the Biotechs industry average (and greater than 0)? (2 checks)
  3. Is the PEG ratio within a reasonable range (0 to 1)? (1 check)
  4. Is the PB ratio less than the Biotechs industry average (and greater than 0)? (1 check)
  5. Moderna has a total score of 0/6, see the detailed checks below.

    Note: We use GAAP Earnings per Share in all our calculations including PE and PEG Ratio.

    Full details on the Value part of the Simply Wall St company analysis model.

Future Performance

 How is Moderna expected to perform in the next 1 to 3 years based on estimates from 11 analysts?

The future performance of a company is measured in the same way as past performance, by looking at estimated growth and how much profit it is expected to make.

Future estimates come from professional analysts. Just like forecasting the weather, they don’t always get it right!
Annual Growth Rate
0%
Expected annual growth in earnings.
Earnings growth vs Low Risk Savings
Is Moderna expected to grow at an attractive rate?
  • Unable to compare Moderna's earnings growth to the low risk savings rate as it is expected to be loss making during the next 1-3 years.
Growth vs Market Checks
  • Unable to compare Moderna's earnings growth to the Germany market average as it is expected to be loss making during the next 1-3 years.
  • Moderna's revenue growth is expected to exceed the Germany market average.
Annual Growth Rates Comparison
Raw Data
DB:0QF Future Growth Rates Data Sources
Data Point Source Value (per year)
DB:0QF Future Earnings Growth Rate Line of Best Fit* through Consensus Estimate Earnings of 11 Analysts 0%
DB:0QF Future Revenue Growth Rate Line of Best Fit* through Consensus Estimate Revenue of 11 Analysts 20.7%
Germany Biotechs Industry Earnings Growth Rate Market Cap Weighted Average 55.2%
Germany Biotechs Industry Revenue Growth Rate Market Cap Weighted Average 24%
Germany Market Earnings Growth Rate Market Cap Weighted Average 14.1%
Germany Market Revenue Growth Rate Market Cap Weighted Average 3.9%

*Line of best fit is calculated by linear regression .

Industry and Market average data is calculated daily.

Learn more about our growth rate calculations in Simply Wall St’s analysis model.

Analysts growth expectations
Raw Data
DB:0QF Analysts Growth Expectations Data Sources
Data Point Source Value
Past Financials Company Filings (3 months ago) See Below
Future Estimates Average of up to 11 Analyst Estimates (S&P Global) See Below
All numbers in USD Millions and using Trailing twelve months (TTM) annual period rather than quarterly.
DB:0QF Future Estimates Data
Date (Data in USD Millions) Revenue Cash Flow Net Income * Avg. No. Analysts
2024-12-31 223 -459 3
2023-12-31 129 -542 3
2022-12-31 84 -451 -612 5
2021-12-31 99 -455 -581 10
2020-12-31 83 -427 -532 11
2020-04-06
DB:0QF Past Financials Data
Date (Data in USD Millions) Revenue Cash Flow Net Income *
2019-12-31 60 -459 -514
2019-09-30 82 -454 -535
2019-06-30 106 -427 -500
2019-03-31 122 -363 -459
2018-12-31 135 -331 -402
2018-09-30 192 -343 -299
2018-06-30 192 -305 -280
2018-03-31 199 -350 -266
2017-12-31 206 -331 -270

*GAAP earnings excluding extraordinary items.

Super high growth metrics
High Growth Checks
  • Moderna is not considered high growth as it is expected to be loss making for the next 1-3 years.
  • Moderna's revenue is expected to grow significantly at over 20% yearly.
Past and Future Earnings per Share
The accuracy of the analysts who estimate the future performance data can be gauged below. We look back 3 years and see if they were any good at predicting what actually occurred. We also show the highest and lowest estimates looking forward to see if there is a wide range.
Raw Data
DB:0QF Past and Future Earnings per Share
Data Point Source Value
Past Financials Company Filings (3 months ago) See Below
Future Estimates Average of up to 11 Analyst Estimates (S&P Global) See Below

All data from Moderna Company Filings, last reported 3 months ago, and in Trailing twelve months (TTM) annual period rather than quarterly.

DB:0QF Future Estimates Data
Date (Data in USD Millions) EPS * EPS High Estimate EPS Low Estimate Avg. No. Analysts
2024-12-31 -1.00 -0.22 -1.44 3.00
2023-12-31 -1.27 -0.95 -1.48 3.00
2022-12-31 -1.51 -1.39 -1.71 4.00
2021-12-31 -1.55 -1.39 -1.76 8.00
2020-12-31 -1.50 -1.34 -1.62 9.00
2020-04-06
DB:0QF Past Financials Data
Date (Data in USD Millions) EPS *
2019-12-31 -1.55
2019-09-30 -1.92
2019-06-30 -2.35
2019-03-31 -3.12
2018-12-31 -4.95
2018-09-30 -4.55
2018-06-30 -4.28
2018-03-31 -4.10
2017-12-31 -4.18

*GAAP earnings excluding extraordinary items.

Performance in 3 years
In the same way as past performance we look at the future estimated return (profit) compared to the available funds. We do this looking forward 3 years.
  • Unable to establish if Moderna will efficiently use shareholders’ funds in the future (Return on Equity greater than 20%) as it is not expected to be profitable.
X
Future performance checks
We assess Moderna's future performance by looking at:
  1. Is the annual earnings growth rate expected to beat the low risk savings rate, plus a premium to keep pace with inflation?
  2. Is the annual earnings growth rate expected to beat the average growth rate in earnings of the Germany market? (1 check)
  3. Is the annual revenue growth rate expected to beat the average growth rate in revenue of the Germany market? (1 check)
  4. Is the annual earnings growth rate expected to be above 20%? (1 check)
  5. Is the annual revenue growth rate expected to be above 20%? (1 check)
  6. Is the Return on Equity in 3 years expected to be over 20%? (1 check)
Some of the above checks will fail if the company is expected to be loss making in the relevant year.
Moderna has a total score of 2/6, see the detailed checks below.

Note 1: We use GAAP Net Income Excluding Exceptional Items for our Earnings in all our calculations.

Full details on the Future part of the Simply Wall St company analysis model.

Past Performance

  How has Moderna performed over the past 5 years?

The past performance of a company can be measured by how much growth it has experienced and how much profit it makes relative to the funds and assets it has available.
Past earnings growth
Below we compare Moderna's growth in the last year to its industry (Biotechs).
Past Earnings growth analysis
We also check if the company has grown in the past 5 years, and whether it has maintained that growth in the year.
  • Moderna does not make a profit and there is insufficient past data to establish if their 5 year on year earnings growth rate was positive.
  • Unable to compare Moderna's 1-year earnings growth to the 5-year average as it is not currently profitable.
  • Unable to compare Moderna's 1-year growth to the Europe Biotechs industry average as it is not currently profitable.
Earnings and Revenue History
Moderna's revenue and profit over the past 5 years is shown below, any years where they have experienced a loss will show up in red.
Raw Data

All data from Moderna Company Filings, last reported 3 months ago, and in Trailing twelve months (TTM) annual period rather than quarterly.

DB:0QF Past Revenue, Cash Flow and Net Income Data
Date (Data in USD Millions) Revenue Net Income * G+A Expenses R&D Expenses
2019-12-31 60.21 -514.02 109.62
2019-09-30 81.58 -535.00 122.02
2019-06-30 106.29 -499.63 112.35
2019-03-31 122.05 -458.66 105.22
2018-12-31 135.07 -401.86 94.25
2018-09-30 191.55 -299.18 72.13
2018-06-30 192.27 -279.63 70.34
2018-03-31 199.14 -265.62 65.00
2017-12-31 205.83 -269.84 64.72
2016-12-31 108.40 -230.31 57.45

*GAAP earnings excluding extraordinary items.

Performance last year
We want to ensure a company is making the most of what it has available. This is done by comparing the return (profit) to a company's available funds, assets and capital.
  • It is difficult to establish if Moderna has efficiently used shareholders’ funds last year (Return on Equity greater than 20%) as it is loss-making.
  • It is difficult to establish if Moderna has efficiently used its assets last year compared to the Europe Biotechs industry average (Return on Assets) as it is loss-making.
  • It is difficult to establish if Moderna improved its use of capital last year versus 3 years ago (Return on Capital Employed) as it is currently loss-making.
X
Past performance checks
We assess Moderna's performance over the past 5 years by checking for:
  1. Has earnings increased in past 5 years? (1 check)
  2. Has the earnings growth in the last year exceeded that of the Biotechs industry? (1 check)
  3. Is the recent earnings growth over the last year higher than the average annual growth over the past 5 years? (1 check)
  4. Is the Return on Equity (ROE) higher than 20%? (1 check)
  5. Is the Return on Assets (ROA) above industry average? (1 check)
  6. Has the Return on Capital Employed (ROCE) increased from 3 years ago? (1 check)
The above checks will fail if the company has reported a loss in the most recent earnings report. Some checks require at least 3 or 5 years worth of data.
Moderna has a total score of 0/6, see the detailed checks below.

Note: We use GAAP Net Income excluding extraordinary items in all our calculations.

Full details on the Past part of the Simply Wall St company analysis model.

Health

 How is Moderna's financial health and their level of debt?

A company's financial position is much like your own financial position, it includes everything you own (assets) and owe (liabilities).

The boxes below represent the relative size of what makes up Moderna's finances.

The net worth of a company is the difference between its assets and liabilities.
Net Worth
  • Moderna is able to meet its short term (1 year) commitments with its holdings of cash and other short term assets.
  • Moderna's cash and other short term assets cover its long term commitments.
Balance sheet
This treemap shows a more detailed breakdown of Moderna's finances. If any of them are yellow this indicates they may be out of proportion and red means they relate to one of the checks below.
Assets
Liabilities and shares
The 'shares' portion represents any funds contributed by the owners (shareholders) and any profits.
  • Low level of unsold assets.
  • Moderna has no debt, it does not need to be covered by short term assets.
Historical Debt
Nearly all companies have debt. Debt in itself isn’t bad, however if the debt is too high, or the company can’t afford to pay the interest on its debts this may have impacts in the future.

The graphic below shows equity (available funds) and debt, we ideally want to see the red area (debt) decreasing.

If there is any debt we look at the companies capability to repay it, and whether the level has increased over the past 5 years.
Raw Data

All data from Moderna Company Filings, last reported 3 months ago.

DB:0QF Past Debt and Equity Data
Date (Data in USD Millions) Total Equity Total Debt Cash & Short Term Investments
2019-12-31 1,174.81 0.00 1,103.00
2019-09-30 1,251.81 0.00 1,058.54
2019-06-30 1,338.55 0.00 1,070.35
2019-03-31 1,446.03 0.00 1,108.92
2018-12-31 1,530.24 0.00 1,521.43
2018-09-30 1,076.43 26.89 1,072.20
2018-06-30 1,148.85 26.68 1,114.86
2018-03-31 625.30 15.69 756.03
2017-12-31 625.30 0.00 756.03
2016-12-31 841.85 12.50 1,058.14
  • Moderna has no debt.
  • Moderna currently has no debt however we can't compare to 5 years ago as we have no data for that period.
CASH RUNWAY ANALYSIS

For companies that have on average been loss making in the past we assess whether they have at least 1 year of cash runway.

  • Moderna has sufficient cash runway for 2.2 years based on current free cash flow.
  • Moderna has sufficient cash runway for 2.3 years if free cash flow continues to grow at historical rates of 35.1% each year.
X
Financial health checks
We assess Moderna's financial health by checking for:
  1. Are short term assets greater than short term liabilities? (1 check)
  2. Are short term assets greater than long term liabilities? (1 check)
  3. Has the debt to equity ratio increased in the past 5 years? (1 check)
  4. Is the debt to equity ratio over 40%? (1 check)
  5. Is the debt covered by operating cash flow? (1 check)
  6. Are earnings greater than 5x the interest on debt (if company pays interest at all)? (1 check)
  7. Moderna has a total score of 6/6, see the detailed checks below.
For companies that are loss making and have been so on average in the past we replace the last 2 checks with:
  1. Does cash and short term investments cover stable operating expenses (recurring G&A and R&D) for more than 3 years? (1 check)
  2. Does cash and short term investments cover growing operating expenses (recurring G&A and R&D) for more than 3 years? (1 check)


Full details on the Health part of the Simply Wall St company analysis model.

Dividends

 What is Moderna's current dividend yield, its reliability and sustainability?

Dividends are regular cash payments to you from the company, similar to a bank paying you interest on a savings account.
Annual Dividend Income
Dividend payments
0%
Current annual income from Moderna dividends. Estimated to be 0% next year.
If you bought €2,000 of Moderna shares you are expected to receive €0 in your first year as a dividend.
Dividend Amount
Here we look how much dividend is being paid, if any. Is it above what you can get in a savings account? It is up there with the best dividend paying companies?
  • Unable to evaluate Moderna's dividend yield against the bottom 25% of dividend payers as the company has not reported any payouts.
  • Unable to evaluate Moderna's dividend against the top 25% market benchmark as the company has not reported any payouts.
Annualized Historical and Future Dividends
It is important to see if the dividend for a company is stable, and not wildly increasing/decreasing each year. This graph shows you the historical rate to count toward your assessment of the stock.

We also check to see if the dividend has increased in the past 10 years.
Raw Data
DB:0QF Annualized Past and Future Dividends
Data Point Source Value
Past Annualized Dividend Yield S&P Global Market Data See Below
Past Dividends per Share Company Filings/ Annualized Dividend Payments See Below
Future Dividends per Share Estimates Average of up to 11 Analyst Estimates (S&P Global) See Below
Europe Biotechs Industry Average Dividend Yield Market Cap Weighted Average of 9 Stocks 1.1%
Germany Market Average Dividend Yield Market Cap Weighted Average of 316 Stocks 3.9%
Germany Minimum Threshold Dividend Yield 10th Percentile 0.9%
Germany Bottom 25% Dividend Yield 25th Percentile 1.7%
Germany Top 25% Dividend Yield 75th Percentile 4.9%

Industry and Market average data is calculated daily.

Note all dividend per share amounts are annualized and not quarterly or other period.

DB:0QF Future Dividends Estimate Data
Date (Data in $) Dividend per Share (annual) Avg. No. Analysts
2024-12-31
2023-12-31
2022-12-31 0.00 2.00
2021-12-31 0.00 3.00
2020-12-31 0.00 3.00
2020-04-06

Learn more about our ratios and growth rates in Simply Wall St’s analysis model >

  • Unable to perform a dividend volatility check as Moderna has not reported any payouts.
  • Unable to verify if Moderna's dividend has been increasing as the company has not reported any payouts.
Current Payout to shareholders
What portion of Moderna's earnings are paid to the shareholders as a dividend.
  • Unable to calculate sustainability of dividends as Moderna has not reported any payouts.
Future Payout to shareholders
  • No need to calculate the sustainability of Moderna's dividends in 3 years as they are not expected to pay a notable one for Germany.
X
Income/ dividend checks
We assess Moderna's dividend by checking for:
  1. Firstly is the company paying a notable dividend (greater than 0.9%) - if not then the rest of the checks are ignored.
  2. Is current dividend yield above the bottom 25% of dividend payers? (1 check)
  3. Is current dividend yield above the top 25% of dividend payers? (1 check)
  4. Have they paid a dividend for 10 years, and during this period has the dividend been volatile (drop of more than 25%)? (1 check)
  5. If they have paid a dividend for 10 years has it increased in this time? (1 check)
  6. How sustainable is the dividend, can Moderna afford to pay it from its earnings today and in 3 years (Payout ratio less than 90%)? (2 checks)
  7. Moderna has a total score of 0/6, see the detailed checks below.


Full details on the Dividends part of the Simply Wall St company analysis model.

Management

 What is the CEO of Moderna's salary, the management and board of directors tenure and is there insider trading?

Management is one of the most important areas of a company. We look at unreasonable CEO compensation, how long the team and board of directors have been around for and insider trading.
CEO
Stéphane Bancel
COMPENSATION $8,948,207
AGE 46
TENURE AS CEO 8.5 years
CEO Bio

Mr. Stéphane Bancel serves as Interim President of Valera LLC. Mr. Bancel is Venture Partner of Flagship Pioneering and a Trustee of the Museum of Science in Boston. Mr. Bancel provides strategic counsel and support to portfolio companies at Flagship Pioneering. He serves as the Founding Chief Executive Officer of Moderna, Inc. (formerly known as Moderna Therapeutics, Inc.) since October 2011. He served as a Senior Advisor of Institut Mérieux SA. He served as the Chief Executive Officer of bioMérieux SA at bioMérieux, Inc. until July 20, 2011. During his five years leading the company, he accelerated the sales growth rate, enhanced its position as a global leader in clinical microbiology and re-accelerated its immunoassay franchise by focusing on high medical value biomarkers. Mr. Bancel served as an Executive Chairman of BG Medicine, Inc from July 2011 to November 1, 2013. From July 2000 to March 2006, Mr. Bancel worked in the United States, Great Britain and Belgium for Eli Lilly laboratories, where he successively served as Managing Director, Executive Director for Global Manufacturing Strategy, Global Supply Chain and U.S. Distribution and Supply Chain Manager. He served as President of Moderna, Inc. From 1995 to 1998, he worked at bioMérieux, where he was In Charge of the industrial microbiology business for the Asia-Pacific region Sales and served as Marketing Director. He has been a Supervisory Director of Qiagen N.V. since June 26, 2013. He serves as a Director of Moderna, Inc. since March 2011 and Tafkak, Inc. Mr. Bancel served as the Chairman of BG Medicine, Inc. since November 1, 2013. He served as the Chairman of bioTheranostics, Inc. He served as a Director of Syros Pharmaceuticals, Inc. since November 21, 2013 until June 08, 2017. He served as a Director of Targanta Therapeutics Corp., from August 2008 to February 25, 2009. He served as Director of BG Medicine, Inc. since January 2010. He served as Director of BG Medicine, Inc. from January 2010 to May 12, 2015. He was elected a 2009 Young Global Leader by the World Economic Forum. He was elected best Chief Executive Officer for Investor Relations in France in 2009 and was ranked 1 Chief Executive Officer in the Biotechnology sector according to the 2011 Thomson Reuters Pan European EXTEL Study. He holds a Master of Engineering degree from École Centrale Paris (ECP), a Master of Science in Chemical Engineering from the University of Minnesota and an M.B.A. from Harvard Business School.

CEO Compensation
  • Stéphane's compensation has been consistent with company performance over the past year, both up more than 20%.
  • Stéphane's remuneration is higher than average for companies of similar size in Germany.
Management Team Tenure

Average tenure and age of the Moderna management team in years:

5.1
Average Tenure
49.5
Average Age
  • The average tenure for the Moderna management team is over 5 years, this suggests they are a seasoned and experienced team.
Management Team

Noubar Afeyan

TITLE
Independent Non Executive Chairman & Member of Technology Advisory Board
COMPENSATION
$530K
AGE
56

Stéphane Bancel

TITLE
CEO & Director
COMPENSATION
$9M
AGE
46
TENURE
8.5 yrs

Stephen Hoge

TITLE
President
COMPENSATION
$5M
AGE
43

Lorence Kim

TITLE
CFO & Treasurer
COMPENSATION
$4M
AGE
45
TENURE
6 yrs

Tal Zaks

TITLE
Chief Medical Officer
COMPENSATION
$5M
AGE
53
TENURE
5.1 yrs

Juan Andres

TITLE
Chief Technical Operations & Quality Officer
COMPENSATION
$4M
AGE
54
TENURE
2.7 yrs

Jennifer Lee

TITLE
Chief Accounting Officer

John Reynders

TITLE
Chief Information Officer
TENURE
6.8 yrs

Melissa Moore

TITLE
Chief Scientific Officer & Member of Scientific Advisory Board
TENURE
3.5 yrs

Lavina Talukdar

TITLE
Head of Investor Relations
TENURE
1 yrs
Board of Directors Tenure

Average tenure and age of the Moderna board of directors in years:

5.1
Average Tenure
58
Average Age
  • The tenure for the Moderna board of directors is about average.
Board of Directors

Noubar Afeyan

TITLE
Independent Non Executive Chairman & Member of Technology Advisory Board
COMPENSATION
$530K
AGE
56
TENURE
8.2 yrs

Stéphane Bancel

TITLE
CEO & Director
COMPENSATION
$9M
AGE
46
TENURE
9.1 yrs

Melissa Moore

TITLE
Chief Scientific Officer & Member of Scientific Advisory Board

Jack Szostak

TITLE
Chairman of Scientific Advisory Board

Israel Ruiz

TITLE
Independent Non Executive Director
COMPENSATION
$503K
AGE
47
TENURE
3.2 yrs

Stephen Berenson

TITLE
Independent Non Executive Director
COMPENSATION
$500K
AGE
58
TENURE
2.5 yrs

Bob Langer

TITLE
Independent Non Executive Director & Member of Scientific Advisory Board
COMPENSATION
$500K
AGE
70

Betsy Nabel

TITLE
Independent Non Executive Director
COMPENSATION
$488K
AGE
67
TENURE
4.3 yrs

Ulrich von Andrian-Werburg

TITLE
Member of Scientific Advisory Board

John Aunins

TITLE
Member of Technology Advisory Board
AGE
58
TENURE
5.9 yrs
Who owns this company?
Recent Insider Trading
  • Moderna individual insiders have sold more shares than they have bought in the past 3 months.
Recent Insider Transactions
Announced Type Name Entity Role Start End Shares Max Price (€) Value (€)
11. Mar 20 Sell Jennifer Lee Individual 09. Mar 20 09. Mar 20 -361 €23.91 €-8,630
18. Feb 20 Buy Paul Sagan Individual 14. Feb 20 14. Feb 20 52,631 €17.52 €922,290
14. Jan 20 Sell Edwin Kania Individual 10. Jan 20 14. Jan 20 -475,000 €18.29 €-8,650,846
11. Dec 19 Sell Noubar Afeyan Individual 10. Dec 19 10. Dec 19 -100,000 €16.95 €-1,695,201
11. Dec 19 Sell Flagship Pioneering Company 09. Dec 19 11. Dec 19 -435,855 €17.12 €-7,387,898
X
Management checks
We assess Moderna's management by checking for:
  1. Is the CEO's compensation unreasonable compared to market cap? (1 check)
  2. Has the CEO's compensation increased more than 20% whilst the EPS is down more then 20%? (1 check)
  3. Is the average tenure of the management team less than 2 years? (1 check)
  4. Is the average tenure of the board of directors team less than 3 years? (1 check)
  5. Moderna has a total score of 0/6, this is not included on the snowflake, see the detailed checks below.


Note: We use the top 6 management executives and board members in our calculations.

Note 2: Insider trading include any internal stakeholders and these transactions .

Full details on the Management part of the Simply Wall St company analysis model.

News

Simply Wall St News

Company Info

Description

Moderna, Inc., a clinical stage biotechnology company, develops therapeutics and vaccines based on messenger RNA for the treatment of infectious diseases, immuno-oncology, rare diseases, and autoimmune and cardiovascular diseases. As of February 14, 2020, the company had 12 programs in clinical trials and a total of 24 development candidates in six modalities comprising prophylactic vaccines, cancer vaccines, intratumoral immuno-oncology, localized regenerative therapeutics, systemic secreted and cell surface therapeutics, and systemic intracellular therapeutics. It has strategic alliances with AstraZeneca, Merck & Co., Vertex Pharmaceuticals, Biomedical Advanced Research and Development Authority, Defense Advanced Research Projects Agency, and Bill & Melinda Gates Foundation, as well as the Coalition for Epidemic Preparedness Innovations. The company was formerly known as Moderna Therapeutics, Inc. and changed its name to Moderna, Inc. in August 2018. Moderna, Inc. was founded in 2010 and is headquartered in Cambridge, Massachusetts.

Details
Name: Moderna, Inc.
0QF
Exchange: DB
Founded: 2010
$11,904,646,056
368,642,548
Website: http://www.modernatx.com
Address: Moderna, Inc.
200 Technology Square,
Cambridge,
Massachusetts, 02139,
United States
Listings
Exchange Symbol Ticker Symbol Security Exchange Country Currency Listed on
NasdaqGS MRNA Common Stock Nasdaq Global Select US USD 07. Dec 2018
DB 0QF Common Stock Deutsche Boerse AG DE EUR 07. Dec 2018
MUN 0QF Common Stock Boerse Muenchen DE EUR 07. Dec 2018
BMV MRNA * Common Stock Bolsa Mexicana de Valores MX MXN 07. Dec 2018
Number of employees
Current staff
Staff numbers
830
Moderna employees.
Industry
Biotechnology
Pharmaceuticals & Biotech
Company Analysis and Financial Data Status
Area Date (UTC time)
Company Analysis updated: 2020/04/06 01:22
End of day share price update: 2020/04/03 00:00
Last estimates confirmation: 2020/03/30
Last earnings filing: 2020/02/27
Last earnings reported: 2019/12/31
Last annual earnings reported: 2019/12/31


All dates and times in UTC. All financial data provided by Standard & Poor’s Capital IQ.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.